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Is the Allergic Rhinitis and its Impact on
Asthma classification useful in daily
primary care practice?
To the Editor:
In 2001, the Allergic Rhinitis and its Impact on Asthma
(ARIA) initiative proposed a new classification for aller-
gic rhinitis (AR) on the basis of the duration of symptoms
and their effect on the quality of life and formulated
evidence-based guidelines for the treatment of this dis-
ease.1 AR is a major primary health care problem, and the
ARIA guidelines were developed primarily to assist gen-
eral practitioners (GPs) in their management of this condi-
tion. The classification scheme is the basis of the stepwise
treatment recommendations and should be tailored to the
AR patient population in daily general practice.
During the pollen season of 2003, we conducted a
cross-sectional survey in general practice in Belgium.
Ninety-five Belgian GPs enrolled 804 patients who pre-
sented with symptoms of AR. For each patient, a question-
naire covering the duration, severity, symptomatology,
and management of the disease was completed. In a pre-
vious article, we described the characteristics of the pa-
tients in the different ARIA classification groups, and we
compared the management of AR in daily primary care
practice with the ARIA recommendations.2 The results
demonstrated that the classification of AR as persistent
and intermittent, on the basis of the duration of disease,
is not equivalent to the previous, unsatisfactory classifica-
tion of AR as perennial or seasonal. These findings are
similar to those from large epidemiological studies in the
general population,3,4 in primary care practice,5 and in
specialty practice.6
On the other hand, the usefulness and validity of the
classification of AR severity as mild or moderate-severe,
on the basis of the impact of AR on quality of life, are not
verified with data. The results of our survey indicate that
moderate-severe AR indeed represents a higher burden of
disease than mild AR, as reflected by the higher scores for
nasal and nonnasal symptoms accompanying AR and the
more complicated diagnostic and therapeutic management
in moderate-severe compared with mild rhinitis.2 An im-
portant finding in our data is the disproportionate size of
the diagnostic groups, with the preponderance of subjects
classified as moderate-severe rhinitis, 89.3%, and only
10.7% classified as mild. These data are similar to results
of a year-round assessment in general practice in France,
in which 93% of the 3052 patients with AR enrolled
were classified with moderate-severe rhinitis.7
We address the imbalance between mild and moderate-
severe AR and propose a refinement of the current ARIA
classification for AR severity.
Allergic Rhinitis and its Impact on Asthma defines the
severity of AR on the basis of 4 quality of life items: (1)
impairment of sleep; (2) impairment of daily activities,
sports, or leisure; (3) impairment of school or work; and
(4) troublesome symptoms. If 1 or more of these items are
present, rhinitis is classified as moderate-severe.1 In our
study, abnormal sleep was reported by 37.1% of the
patients; impairment of daily activities, sports, or leisure
by 71.3%; impairment of work or school by 53.2%; and
troublesome symptoms by 77.6%.2 Because 86.9% of
the patients with moderate-severe AR considered their
symptoms troublesome and only 9.8% of the patients
reported troublesome symptoms in the absence of im-
pairment of daily activities/sports/leisure, school/work, or
TABLE I. Symptom scores in the new mild, moderate,
and severe AR groups*
Mild AR
(165)
Moderate AR
(369)
Severe AR
(270) P
Rhinorrhea! 52.1 60.7 61.5 NS
Nasal congestion! 42.4 61.5 72.2 <.0001
Nasal itch! 35.1 51.8 50.4 .007
Sneeze! 55.8 61.0 67.4 .01
Eye symptoms! 33.3 37.9 45.9 <.0001
Headache! 4.2 12.5 19.2 <.0001
Somnolence! 1.8 9.8 13.3 .0001
Troublesome
symptoms (%)
47.9 81.4 90.4 <.0001
NS, Not significant.
*Statistical analyses with x2 test for trend (Medcalc, version 8.1.0.0,
Medcalc Software, Mariakerke, Belgium).
P < .05 5 statistically significant.
!Each symptom score is expressed as the percentage of patients with a
score of 3 or 4 (symptoms were scored on a 4-point scale evaluating
whether AR manifests by these symptoms: 1 5 never/rarely, 2 5
occasionally, 3 5 frequently, or 4 5 always).
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sleep, the report of troublesome symptoms does not add
appreciably to the assessment of disease severity. Further-
more, impairment of daily activities/sports/leisure and im-
pairment of school/work both lead to a diminished quality
of the active daily life, and we found an important overlap
between these 2 items. Although more patients experi-
enced discomfort from AR during their personal than dur-
ing their professional life, 91.1% of those who reported
problems at school or work were also bothered during
daily activities, sports, or leisure.
On the basis of these findings, we suggest a modifi-
cation in the current assessment of AR severity defined
by ARIA. We propose to eliminate the question on the
troublesome symptoms as a key issue in the assessment of
AR severity, and to recombine the question on impairment
of daily activities, sports, and leisure and the question on
the impairment of school or work into 1 question evalu-
ating the quality of the active daily life.
Taken together, this results in 2 questions to evaluate
the severity of AR:
1. Do your symptoms of AR cause sleep disturbance?
2. Do your symptoms of AR cause impairment of
your daily personal (daily activities, leisure, sports)
and/or professional life (school, work)?
In this model, the severity of AR is classified into 3
groups, with patients responding ‘‘no’’ to both questions
classified as mild, patients answering ‘‘yes’’ to 1 of the 2
questions as moderate, and patients answering ‘‘yes’’ to
both questions as severe.
Categorization of the 804 patients from our survey
according to this empirical model resulted in 20.5% with
mild rhinitis, 45.9% with moderate rhinitis, and 33.6%
with severe rhinitis. Table I compares symptom scores and
Table II the diagnostic and therapeutic management in the
new mild, moderate, and severe AR groups.
For all symptom scores except rhinorrhea, a linear
increasing trend was found from mild to moderate to
severe AR. Furthermore, the proportion of patients con-
sidering their symptoms troublesome, the degree of al-
lergy testing, and the prescription rate of nasal and oral
glucocorticosteroids demonstrated a significant trend up-
ward with increasing AR severity category.
In conclusion, we propose to categorize the severity
of AR into 3 instead of 2 groups, which in turn allows a
more gradual stepwise therapeutic approach. On the basis
of the results of our study in general practice, we suggest
a modification in the current assessment of AR severity,
using the 4 questions defined by ARIA. We here propose
a very easy to use and to remember combination of 2
questions: 1 evaluating the patient’s quality of daily life
and 1 evaluating the patient’s quality of sleep.
Classification of our patient population according to
this empirical model results in 3 important groups, with the
moderate group containing most patients. The difference
in disease severity among these 3 newly defined groups is
reflected by the increasing symptom scores, the higher
degree of allergy testing, and increased prescription of
glucocorticosteroids from mild to moderate to severe AR.
Of course, this proposed modification in classification
for AR severity needs to be validated in large patient
groups. Because the ARIA guidelines were mainly devel-
oped for GPs, it is particularly important that the classi-
fication is applicable to the patient population in primary
care practice. However, it would also be interesting to
evaluate which types of patients with AR remain undiag-
nosed in the general population and which types are found
in specialist practice.
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TABLE II. Diagnostic and therapeutic management in
the new mild, moderate, and severe AR groups*
Mild
AR (165)
Moderate
AR (369)
Severe
AR (270) P
Allergy testing (ever) (%) 43.6 51.2 64.4 <.0001
Treatment prescribed (%)
Oral antihistamines 70.3 84.8 85.9 .0002
Nasal antihistamines 11.5 8.1 9.3 NS
Nasal glucocorticosteroids 46.7 54.7 70.0 <.0001
Oral glucocorticosteroids 3.0 3.8 8.9 .004
Nasal decongestants 17.6 15.4 23.7 NS
Topical eye medication 14.5 19.0 16.7 NS
Specialist referral (%) 7.9 6.2 13.3 .02
NS, Not significant.
*Statistical analyses with x2 test for trends (Medcalc version 8.1.0.0).
P < .05 5 statistically significant.
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